

Variable	Confirmed case N = 1,034	Not confirmed N = 1,485	p-value ¹
HIV status, n (%)			<0.001
Person with HIV	292 (86%)	634 (94%)	
Person without HIV	37 (11%)	37 (5.5%)	
Unknown	10 (2.9%)	1 (0.1%)	
Missing/Unknown	695	813	
ever hospitalized, n (%)			<0.001
Yes	99 (13%)	76 (6.1%)	
No	626 (82%)	1,147 (91%)	
Unknown	41 (5.4%)	33 (2.6%)	
Missing/Unknown	268	229	
Length of hospitalization, Median (Q1, Q3)	8.0 (5.0, 13.0)	7.0 (5.0, 11.0)	0.6
Missing/Unknown	969	1,424	
Escalation of care, n (%)			>0.9
Yes	1 (1.9%)	1 (3.4%)	
No	52 (98%)	28 (97%)	
Unknown	0 (0%)	0 (0%)	
Missing/Unknown	981	1,456	
supplemental oxygen, n (%)			<0.001
Yes	4 (0.9%)	16 (5.5%)	
No	447 (99%)	273 (93%)	
Unknown	1 (0.2%)	4 (1.4%)	
Missing/Unknown	582	1,192	
receive nasogastric fluids, n (%)			>0.9
Yes	0 (0%)	0 (0%)	
No	60 (100%)	37 (100%)	
Unknown	0 (0%)	0 (0%)	
Missing/Unknown	974	1,448	
receive IV fluids during course monkeypox infection, n (%)			0.4
Yes	5 (8.3%)	1 (2.7%)	
No	55 (92%)	36 (97%)	
Unknown	0 (0%)	0 (0%)	
Missing/Unknown	974	1,448	
receive analgesia for pain management, n (%)			<0.001
Yes	161 (46%)	57 (35%)	
No	183 (53%)	91 (57%)	
Unknown	3 (0.9%)	13 (8.1%)	
Missing/Unknown	687	1,324	

¹

Fisher's exact test; Pearson's Chi-squared test; Wilcoxon rank sum test

Variable	Confirmed case N = 1,034	Not confirmed N = 1,485	p-value ¹
receive antibiotics during course monkeypox infection, n (%)			<0.001
Yes	163 (47%)	110 (64%)	
No	186 (53%)	55 (32%)	
Unknown	1 (0.3%)	8 (4.6%)	
Missing/Unknown	684	1,312	
receive antifungals during course monkeypox infection, n (%)			<0.001
Yes	5 (1.5%)	17 (10%)	
No	319 (98%)	135 (83%)	
Unknown	1 (0.3%)	11 (6.7%)	
Missing/Unknown	709	1,322	
experimental antiviral during course monkeypox infection, n (%)			>0.9
Yes	0 (0%)	0 (0%)	
No	60 (100%)	37 (100%)	
Unknown	0 (0%)	0 (0%)	
Missing/Unknown	974	1,448	

¹

Fisher's exact test; Pearson's Chi-squared test; Wilcoxon rank sum test